ClinicalTrials.gg

Program

alpha 1-Antitrypsin

Also written as “Alpha-1 MP”, “GLASSIA” and “Alpha1-proteinase inhibitor”.

Its studies are mostly in alpha 1-Antitrypsin Deficiency · Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema · Graft vs Host Disease · Diabetes Mellitus, Type 1, led by 4 companies.

Furthest: phase 4, since Feb 20, 200626 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grifols131 open or runningphase 3since Feb 20, 2006Sep 12, 2005Sep 2028phase 3 · NCT02796937
Takeda70 open or runningphase 4since Nov 3, 2006Nov 3, 2006none ahead
CSL31 open or runningphase 4since Dec 2, 2005Dec 2, 2005Sep 15, 2033phase 4 · NCT07326592
Kamada30 open or runningphase 3since Dec 17, 2019Feb 24, 2011none ahead

Also a collaborator on its studies: baxalta-innovations-gmbh-now-part-of-shire.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Sep 12, 2005.

  1. Nov 27, 2013Phase 2 study in Diabetes MellitusKamada · NCT02005848 · 70 enrolled · Israel
  2. Mar 11, 2014Phase 2 study in Diabetes Mellitus, Type 1Grifols · NCT02093221 · 76 enrolled · United States
  3. Oct 31, 2014Phase 3 study in Alpha₁-Antitrypsin DeficiencyGrifols · NCT02282527 · 32 enrolled · United States
  4. Aug 14, 2015Phase 3 study in alpha 1-Antitrypsin DeficiencyTakeda · NCT02525861 · 34 enrolled · United States, Canada
  5. Mar 23, 2016Phase 3 study in Pulmonary Disease, Chronic ObstructiveTakeda · NCT02722304 · 7 enrolled · United States, Australia, Canada
  6. Jun 3, 2016Phase 3 study in Pulmonary EmphysemaGrifols · NCT02796937 · 290 planned · United States, Australia, Canada and more
  7. Aug 12, 20162 phase 2 studies in alpha 1-Antitrypsin DeficiencyGrifols · NCT02870348, NCT02870309
  8. Oct 24, 2016Phase 3 study in Graft vs Host DiseaseTakeda · NCT02956122 · 1 enrolled · United States
  9. Nov 15, 2019Phase 3 study in Graft vs Host DiseaseCSL · NCT04167514 · 136 enrolled · United States
  10. Dec 17, 2019Phase 3 study in alpha 1-Antitrypsin DeficiencyKamada · NCT04204252 · 98 enrolled · Belgium, Finland, Ireland and more
  11. Jun 17, 2020Phase 4 study in Pulmonary Disease, Chronic ObstructiveTakeda · NCT04440488
  12. Jul 28, 2020Phase 2 study in COVID-19Grifols · NCT04495101 · 100 enrolled · Spain
  13. Jun 17, 2022Phase 4 study in Pulmonary Disease, Chronic ObstructiveTakeda · NCT05466747
  14. Jan 7, 2026Phase 4 study in alpha 1-Antitrypsin DeficiencyCSL · NCT07326592 · 270 planned · Denmark

Ahead

  1. Sep 2028Primary completion: phase 3 study in Pulmonary EmphysemaGrifols · NCT02796937
  2. Sep 15, 2033Primary completion: phase 4 study in alpha 1-Antitrypsin DeficiencyCSL · NCT07326592

TargetBeta

ELANE →read by rule
“Leukocyte elastase inhibitor”ChEMBL 37, by rule

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07326592alpha 1-Antitrypsin Deficiency · Denmark4RecruitingCSLSep 15, 2033270
NCT05466747Pulmonary Disease, Chronic Obstructive4WithdrawnTakedaApr 26, 20270
NCT04495101COVID-19 · Spain2CompletedGrifolsApr 26, 2021100
NCT04440488Pulmonary Disease, Chronic Obstructive4WithdrawnTakedaSep 12, 20250
NCT04204252alpha 1-Antitrypsin Deficiency · Belgium, Finland, Ireland and more3TerminatedKamadaFeb 19, 202698
NCT04167514Graft vs Host Disease · United States3CompletedCSLSep 11, 2023136
NCT02956122Graft vs Host Disease · United States3TerminatedTakedaMay 3, 20181
NCT02870348alpha 1-Antitrypsin Deficiency · Japan2CompletedGrifolsFeb 16, 20214
NCT02870309alpha 1-Antitrypsin Deficiency · Japan2CompletedGrifolsMar 15, 20174
NCT02796937Pulmonary Emphysema · United States, Australia, Canada and more3By invitationGrifolsSep 2028290
NCT02722304Pulmonary Disease, Chronic Obstructive · United States, Australia, Canada3TerminatedTakedaSep 14, 20187
NCT02525861alpha 1-Antitrypsin Deficiency · United States, Canada3CompletedTakedaJul 29, 202034
NCT02282527Alpha₁-Antitrypsin Deficiency · United States3CompletedGrifolsJan 201632
NCT02093221Diabetes Mellitus, Type 1 · United States2TerminatedGrifolsJan 201776
NCT02005848Diabetes Mellitus · Israel2CompletedKamadaFeb 201770
NCT01983241Pulmonary Emphysema · United States, Argentina, Australia and more3CompletedGrifolsJul 7, 2026345
NCT01684410Cystic Fibrosis · United States2CompletedGrifolsOct 201330
NCT01651351alpha 1-Antitrypsin Deficiency · United States4CompletedTakedaJan 16, 201330
NCT01304537Diabetes Mellitus, Type 1 · Israel2CompletedKamadaNov 201224
NCT01213043Emphysema · United States2CompletedGrifolsJan 201230
NCT00486837Cystic Fibrosis2CompletedGrifolsJun 200472
NCT00396006alpha 1-Antitrypsin Deficiency · Australia, New Zealand4CompletedTakedaDec 14, 200721
NCT00301366alpha 1-Antitrypsin Deficiency · United States, United Kingdom3CompletedGrifolsMar 200738
NCT00295061alpha 1-Antitrypsin Deficiency · United States3CompletedGrifolsFeb 200724
NCT00261833alpha 1-Antitrypsin Deficiency · United States, Australia, Canada and more4CompletedCSLSep 2012180
NCT00263887alpha 1-Antitrypsin Deficiency · Denmark, Sweden, United Kingdom2CompletedGrifolsJan 200777

How it is read

Names in the registry

  • “Alpha-1 MP”, 5 entries
  • “GLASSIA”, 2 entries
  • “Alpha1-proteinase inhibitor”, 2 entries
  • “Alpha1-Proteinase Inhibitor (Human)”, 2 entries
  • “CE1226”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.